The HERO™ Initiative by Accelovance accelerates and advances promising early phase oncology clinical research.
Together, we'll drive cancer research forward.
What is HERO™?
Helping Early Research in Oncology
HERO™ provides emerging and established Biotech and Pharma Sponsors with a focused CRO solution and an integrated site network specializing in early phase oncology clinical studies. Our unique operation model propels you through the Proof of Concept phase faster and more efficiently, placing your cancer therapy on the road to success. HERO™ offers you the scale, expertise, and optimized technologies needed for your early phase oncology clinical research.
Why Should You Choose HERO™?
Do You Have A Cancer Therapy That Shows Promise? Get On Your Way To FDA Approval Faster & Easier.
The oncology research field is getting more competitive and trial designs are increasing in complexity. The pace of novel ideas continues to accelerate with rapid advancements in technology, science, and medicine. More frequently, cancer therapies are targeting small subsets of patients with rare mutations or patients that have been treated with a very specific therapeutic regimen. We understand your job is hard, and thus HERO™ was born to make the trial process easier. Whether you have a biomarker targeted therapy and or a combination immuno-oncology trial, HERO™ has you covered.
HERO™ is a complete service offering, dedicated solely to advancing early phase cancer clinical trials. Our integrated CRO and site solutions get you the patients you need, faster than ever before. We have created automated technologies and systems, tailored to early phase oncology studies, to expedite your trial while keeping costs down. The HERO™ team of oncology experts work with you to customize your protocol and study design for an optimal outcome. Our goal is to get you through that critical early stage of testing and on your way to FDA approval, with the shared mission of bringing products to market that save lives.
We provide our clients with the scale, expertise, and senior management commitment to maintain immediate and consistent engagement with your team at all times throughout the course of your program, to ensure the successful execution and delivery of your proof of concept studies. HERO™ is our pledge to create more fruitful relationships, deliver a higher degree of therapeutic expertise, and the opportunity to do better, more efficient cancer clinical research.
What Can HERO™ Do For Your Cancer Therapy?
The Benefits of Working with a Specialized Cancer CRO
Oncology Site Network
Global Reach & Cancer Expertise
Accelovance's extensive oncology site network includes 250 independently owned research locations across the globe with more than 1,000 Oncologists. With access to a wide variety of specialties and expertise, we can provide both broad based feasibility and unique access to the right oncology patients your study needs.
- Global Site Partnerships
- Dedicated Oncology Staff
- Access to KOLs
- Complete oncology therapeutic area expertise, including rare disease
Get Started Faster
Faster Start-Up Times: 6-12 Weeks
Most cancer CROs average 6-9 months for early phase trial start-ups. But when time is of the essence, and every lost day can cost upwards of $1MM, we know how critical a simple, thorough, streamlined start-up is to your oncology development program. Our goal is to help expedite getting your cancer therapy on the market.
- Pre-Negotiated Site MSAs
- Expedited Budgets & Contracts
- Feasibility Services
- Study, Budget & Timeline Planning
Robust Patient Pipeline For Proactive Enrollment
With our extensive array of 250+ global site partners, each year our site community reaches more than 1 million cancer patients spanning a wide range of indications. This reach, combined with our CRO's operational experitse, provides an ideal backbone and facilitates rapid activation of your clinical program.
- Established and reliable site relationships, critical for on-time delivery and rapid patient recruitment
- Just-in-Time patient enrollment solutions available for expediting study timelines
- Flexibility to manage study size, trial speed, and patient access
Technology Tailored For Early Phase Cancer Research
Our novel solutions are designed to meet the unique demands of your Phase I/II oncology study. From Regulatory to Data Management, and from Monitoring to Pharmacovigilance, our solutions are cross-functional and accelerate access, ensuring data accuracy and compliance, and improving cost efficiency.
- Feature-rich CTMS offering real-time data access and analytics hub for performance and risk management
- Expedited EDC deployment optimized for early phase oncology
- Pre-built eCRF and TFL library for cost reductions
Meet The HERO™ Team
Your Dedicated Oncology Partners
With HERO™, you get a so much more than an oncology CRO. You get true partners to guide you through the hurdles and nuances of oncology clinical research. From pre-study design, to enrolling the right patients, to oversight of you phase 1 trial for cancer, with HERO™ you get the industry expertise of a large CRO without the lofty price tag. Our senior management and scientific experts are is as committed to your oncology compound's success as you are, meaning we are dedicated to being there before, during, and after your trial. Learn more about the team below.
Jamie Oliver, Pharm. D.
Chief Scientific Officer
Dr. Jamie Oliver, Chief Scientific Officer, has supported more than 25 FDA submissions (IND to NDA) for oncology drugs and biologics. His extensive experience covers biologics, small molecule and nanoparticle oncology products. His breadth of work allows him to effectively guide Sponsors to optimize your programs from pre-clinical to NDA. Dr. Oliver provides input and development strategies as part of Accelovance's oncology consulting team in collaboration with Harish Dave, Chief Medical Officer.
Harish Dave, M.D.
Chief Medical Officer
Dr. Harish Dave, board certified oncologist, has been involved in over 100 clinical trials. He leads our Medical Affairs & Drug Safety group where he leverages over 25 years' experience gained from academia, as a principal investigator, and industry professional. Dr. Dave provides input and development within our Oncology consulting team along with Jamie Oliver, Chief Scientific Officer.